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Abstract
Estimation of left ventricular (LV) mass has both prognostic and therapeutic value independent of traditional risk 
factors. Unfortunately, LV mass evaluation has been underestimated in clinical practice. Assessment of LV mass can be 
performed by a number of imaging modalities. Despite inherent limitations, conventional echocardiography has 
fundamentally been established as most widely used diagnostic tool. 3-dimensional echocardiography (3DE) is now 
feasible, fast and accurate for LV mass evaluation. 3DE is also superior to conventional echocardiography in terms of LV 
mass assessment, especially in patients with abnormal LV geometry. Cardiovascular magnetic resonance (CMR) and 
cardiovascular computed tomography (CCT) are currently performed for LV mass assessment and also do not depend 
on cardiac geometry and display 3-dimensional data, as well. Therefore, CMR is being increasingly employed and is at 
the present standard of reference in the clinical setting. Although each method demonstrates advantages over 
another, there are also disadvantages to receive attention. Diagnostic accuracy of methods will also be increased with 
the introduction of more advanced systems. It is also likely that in the coming years new and more accurate diagnostic 
tests will become available. In particular, CMR and CCT have been intersecting hot topic between cardiology and 
radiology clinics. Thus, good communication and collaboration between two specialties is required for selection of an 
appropriate test.
Introduction
Left ventricular hypertrophy (LVH) is an unfavorable
condition, which is consistently and strongly associated
with significant cardiovascular morbidity and mortality
[1]. In addition, left ventricular (LV) mass portends poor
patient prognosis independent of traditional risk factors
[2]. Furthermore, numerous therapeutic agents are
observed to promote LV mass reduction in parallel with
improved clinical outcome [3]. As a result, LV mass is
suggested as a regular study finding of any cardiac imag-
ing modality [4].
LV mass determination by various imaging modalities
is principally based on shell volume, which is obtained as
the difference of epicardial and endocardial volumes.
Shell volume is subsequently converted to mass by multi-
plying with the specific density of myocardial tissue (usu-
ally taken as 1.05 g/mL).
Individual variation in body size influences the assess-
ment of LV mass. Indexing is of importance to differenti-
ate between health and disease, to assess the severity of
disease, to allow comparisons among varying body size,
and to recognize alterations over time. LV mass may be
expressed as an index for some variables of body size. The
best method for LV mass indexing is still under debate.
Different methods of indexation result in considerably
different prevalence of LVH [5]. Some investigators have
traditionally indexed LV mass to body surface area [6].
However, indexing by body surface area may inappropri-
ately normalize LV mass and must be critically ques-
tioned [7]. Normalization for the allometric power of its
r e l a t i o n  t o  b o d y  h e i g h t  ( h e i g h t 2.7 ) provides a greater
attributable risk than other methods of indexation [8].
Indexing to height in meters to the power 2.7 successfully
facilitates identification of LVH among obese subjects, as
well [9]. Nevertheless, lean body mass was found to be
more ideal than height and body surface area for indexing
LV mass (7). Along with these, identification of LV mass
needs to take into account the influence of different eth-
nic groups and sexes [6].
The accurate measurement of LV mass is difficult,
partly due to the oblique angle between heart and chest,
continuous movement of the heart, and the lack of a
proper technique for imaging the whole left ventricle. Ini-
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tial measurements with electrocardiography (ECG) data
were insensitively and nonspecifically surrogate markers
for LVH. Imaging modalities have overwhelmingly super-
seded the ECG over time. Plenty of diagnostic imaging
modalities have been used to asses LV mass. Unfortu-
nately, LV mass evaluation has been underestimated in
clinical practice, thus not taking full benefit of the
acquired data. We are going to discuss echocardiography,
cardiovascular computed tomography (CCT), cardiovas-
cular magnetic resonance (CMR), single photon emission
computed tomography (SPECT) and contrast ventricu-
lography (CV) for LV mass assessment. It is to be known
that none of the imaging modalities is actually performed
for only LV mass assessment.
Echocardiography
The past few decades have seen echocardiography evolve
into a cornerstone of modern cardiac investigation. Grad-
ually, various ultrasound-based techniques with burgeon-
ing technologic improvements have been invented,
investigated, and then integrated. Image quality has
become better, often generating images comparable with
with those of CMR. Hence, echocardiography has been
used essentially to provide mechanistic insights on car-
diac morphology such as LV mass. Routine calculation of
LV mass should be an integral part of an echocardio-
graphic examination [10]. Echocardiography is not only
of use in assessing LV mass but also of use in demonstrat-
ing reduction in LV mass after therapy [3]. Echocardiog-
raphy constitutes to be the first choice cardiac imaging
modality for assessment of LV mass. Moreover, echocar-
diography may further display LVH distribution pattern.
Motion-mode (M-mode), 2-dimensional echocardiog-
raphy (2DE) and finally 3-dimensional echocardiography
(3DE) attract attention for LV mass assessment.
M-mode Echocardiography
First echocardiographic modality that is to be offered for
L V  m a s s  e v a l u a t i o n  i s  M - m o d e  e c h o c a r d i o g r a p h y .  M -
mode echocardiography was one of the earliest modali-
ties of echocardiography to come into clinical use. This
modality records the position and motion of echoes aris-
ing from intracardiac structures with regard to time, pro-
ducing one-dimensional information. LV mass detection
and quantification can be clearly estimated from linear
measurements by employing American Society of
Echocardiography (ASE) recommendations (figures 1
and 2) [11]. LV mass by M-mode was in close correlation
with necropsy, reinforcing this method [12].
L V  m a s s  i s  c a l c u l a t e d  b y  c u b i n g  f o r m u l a ,  w h i c h
assumes that LV is represented by prolate ellipse. M-
mode echocardiography is useful for quantitating LV
mass when ventricles are geometrically uniform for this
reason.
Thanks to its wide availability, moderate expense, ana-
tomic and prognostic validation, and lack of radiation,
contrast agent, or claustrophobia, M-mode echocardiog-
raphy has been used widely for estimating LV mass in
clinical trials [13,14]. Another useful aspect of M-mode
imaging is its easily analyzable depiction of continuous
motion versus time with high temporal resolution, which
makes it useful for timing of cardiac events. M-mode also
yields good interface definition of LV chamber and this
has been further improved by 2D guidance.
Although measurement of LV mass using M-mode has
proved to be the most efficient method and widely used
in clinical and research, there are definite disadvantages
of this method such as need for geometric assumption.
This assumption may lead to inaccuracy that may occur
with altered shape of heart, for example, aneurysm,
hypertrophy, and wall motion abnormalities [15]. Since
LV mass is estimated by the geometric cubing formula,
small errors in these measurements are amplified to the
third power. Secondly, it may not always reflect the true
minor-axis dimension of LV in parasternal long axis (fig-
ures 3 and 4). An optimally oriented M-mode cursor by
2D guidance may be beneficial in this setting [10]. If 2D
guidance is not available, direct 2D measurements may be
alternatively substituted and is considered more accurate
[10,16].
Figure 1 M-mode left ventricular measurements are obtained in 
parasternal long axis from leading edge to leading edge tech-
nique.Celebi et al. Cardiovascular Ultrasound 2010, 8:19
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In other words, M-mode method is reasonable to use
for normally shaped ventricles, but it is likely to give erro-
neous results in abnormally shaped ventricles. However,
this method is presently the only one recommended in a
guideline for determining LVH as subclinical organ dam-
age [17].
2-Dimensional Echocardiography
The second modality of echocardiography for LV mass
evaluation is 2DE. LV mass can directly be computed by
2D linear measurements and standards have been estab-
lished by ASE to support synergy in measurments
[10,16,18]. LV mass can also be calculated from planime-
tered dimensions of 2D images obtained during real-time
transthoracic imaging with the area-length or truncated-
ellipsoid formulas. This specific methodology for 2D esti-
mation of LV mass has good agreement with autopsy [19].
Utilization of 2DE overcomes the common problem of
oblique parasternal images that result in overestimation
of cavity and wall dimensions from M-mode echocar-
diography. 2DE is also preferred to M-mode echocardiog-
raphy in the case of regional wall motion abnormalities,
because M-mode modality identifies the function of the
basal segments only rather than whole LV segments.
Thus, 2DE has widely supplanted isolated M-mode linear
measurements.
Some limitations are also encountered with this modal-
ity. A difficult echo window usually does not let to obtain
accurate delineation of endocardial borders. This con-
finement hinders quantification of LV mass. This has
l a r g e l y  b e e n  r e s o l v e d  b y  a d m i n i s t r a t i o n  o f  a  c o n t r a s t
agent, which is reported to be safe [20]. However, the risk
of serious cardiopulmonary reactions of contrast agent is
highlighted and it is recommended to closely monitor
high-risk patients with pulmonary hypertension or unsta-
ble cardiopulmonary conditions [21]. Patients with severe
intracardiac shunt or hypersensitivity to the agent are
absolute contraindications to emphasize [20]. While
Figure 2 M-mode cursor position is perpendicular to interven-
tricular septum and posterior wall of the ventricle at the mitral 
valve chordae level, reflecting minor-axis dimension.
Figure 3 Minor-axis dimension is overestimated due to tangen-
tial measurement in M-mode echocardiography (4.99 cm).
Figure 4 The true minor axis is obtained from 2-DE (4.61 cm).Celebi et al. Cardiovascular Ultrasound 2010, 8:19
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using 2D linear measurments, ultrasound interrogation
angle should be perpendicular to the endocardium as
much as possible and length of LV should be maximized
for more accurate LV mass measurement [3]. Finally, it is
operator-dependant, thereby requiring some standards to
improve reproducibility and quality of studies [5,22]. A
core laboratory with sufficient experience may also help
determining better reproducibility and decreasing opera-
tor variability, especially when employed in clinical trials
[6]. In contrast to other techniques, it interactively
requires a strong cerebral-to-arm connection and vice
versa throughout the examination.
In conclusion, an optimal method for LV mass by
echocardiography should be safe, rapid, reliable, cost-
effective, and widely applicable in order to be utilized
routinely in a busy clinical laboratory. 2DE remarkably
seems to fulfill these criteria.
3-Dimensional Echocardiography
3DE should be the next logical step for assessment of LV
mass. Newer matrix array transducers allow real time 3-
dimensional (3D) visualization of entire heart by acquir-
ing a pyramidal image. By means of this, 3DE is a novel
use of echocardiography to display the 2 dimensional
imaging planes of cardiac structures within the 3D data
set.
Recently, 3DE has demonstrated incremental value
about LV mass over conventional echocardiographic
modalities (M-mode, 2DE) in different patient popula-
tions [18,23]. The major strength of 3DE is the geometric
assumption free accurate imaging of cardiac structures.
As mentioned before, conventional echocardiographic
modalities are limited mainly by inaccuracies and varia-
tions caused by use of geometric assumptions in case of
asymmetric LV geometry and unintended use of oblique
planes. 3DE, based on the assessment of a larger number
of tomographic views, resolves these limitations. 3DE
correspondingly has the advantage of reducing depen-
dence on geometric models and reducing error based on
angulated images [6,24]. Thus, 3DE offers LV mass deter-
mination substantially comparable to magnetic reso-
nance imaging, as for global LV volumes [25]. This
correlation between 3DE and CMR has also been stron-
ger than that has been between conventional echocar-
diography and CMR [26]. Interobserver variability of
real-time 3 dimensional echocardiography (RT3DE) was
additionally reported to be significantly lower than that of
2DE, supporting its superiority [27]. This superiority has
already been anatomically in agreement with autopsy
findings [24]. 3DE and CMR also produce comparable
results in terms of LV mass with similar interobserver
variability [28]. As 3DE is less costly and more attainable,
it is modality of choice for serial follow-up.
Besides, 3DE may provide comprehensive evaluation of
the cardiovascular structure in addition to LV mass eval-
uation, which overcomes the limitations of conventional
methods [29]. 3DE also shows promise in the assessment
of congenital heart disease, thereby influencing clinical
management and perhaps obviating the need for CMR in
some cases [30]. Moreover, 3DE is less dependent on
operator practice and help to compensate operator inex-
perience when compared to conventional echocardiogra-
phy.
3DE was previously reported to cumbersome, time-
consuming, and difficult to perform compared to conven-
tional methods. These technical complexities have lim-
ited its widespread application in clinical practice and
research [23]. Despite these drawbacks, clinical use of
3DE is recently urged by the marked reduction in acquisi-
tion time and the unique possibility of on-line rendering
on the ultrasound system. Moreover, the time expendi-
ture for 3DE using the semiautomatic algorithms was
similar compared with that for 2DE [15]. The time
needed for the acquisition and analysis of RT3DE data
were further acceptable in another report [31]. It has even
been offered as an accurate and time-saving option in
clinical practice [24].
Care must be taken to include the entire LV cavity
within the pyramidal scan volume. 3DE provides accurate
L V mass when entire L V is covered in the 3D pyramid
[24]. Consequently, 3DE is not yet clearly suited for the
assessment of patients with severe dilated cardiomyopa-
thy, ventricular aneurysms, or ventricles with heavy tra-
b e c u l a e  a s  i t  m a y  n o t  b e  p o s s i b l e  t o  d i s p l a y  p o i n t  o f
interest structure into the pyramidal scan volume. There-
fore, there needs to be further studies to define better the
applicability of this technique in these populations.
3DE echocardiography allows perspectives not achiev-
able conventionally. 3DE is feasible in the clinical setting
and provides fast and accurate assessment of LV mass,
which is superior to conventional echocardiographic
methods, especially in dsitroted hearts. This leads to
greater sensitivity and reduced sample size. The recent
advances in the transducer and computer software tech-
nology may further improve the accuracy and reproduc-
ibility of the technique. With increasing clinical
experiences in 3DE, visualization and quantitation of car-
diovascular structure and function will improve.
Cardiovascular Computed Tomography
Computed tomography (CT) is an emerging modality for
the noninvasive assessment of cardiac anatomy and func-
tion. It is named as CCT by a recent statement for cardio-
vascular field and this represents a specialized use of CT
[32]. Multidetector CT (MDCT) has improved temporal
and spatial resolutions, thereby allowing successful evalu-
ation of coronary anatomy and cardiac morphology. StateCelebi et al. Cardiovascular Ultrasound 2010, 8:19
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of the art CT practice is capable of concomitant LV mass
assessment. Besides, there has been a high correlation for
LV mass evaluated by CCT and CMR, so that CCT is
offered as a strong alternative for patients with contrain-
dications to CMR [33]. This finding was confirmed in
another study comparing CT with echocardiography
[34]. In the light of these data, LV mass estimation has
been encouraged in a routine coronary CT angiography
report at present [35].
Semiautomatic analysis software has simplified endo-
cardial and epicardial contour detection in a significantly
shorter period with the same reliability. Despite this, this
algorithm overestimated LV mass compared with manual
contour tracing [36]. On the other hand, CCT with semi-
automatic software is still reported to accurately quantify
L V  s i z e  a n d  f u n c t i o n  i n c l u d i n g  L V  m a s s  c o m p a r e d  t o
CMR [33]. Objective quantification of LV function using
semiautomatic software analysis is feasible, accurate, and
time-effective.
Patients with heart failure and distorted ventricles seem
to benefit the most from CCT to elucidate etiolgy.
Because information in terms of LV function or mass by
CCT, complement already acquired data concerning cor-
onary anatomy [37]. Thus, CCT is preferred to CMR in
view of its ability to provide superb demonstration of cor-
onary anatomy and to give excellent information about
LV mass at the same time in these patient groups [38].
To best of our knowledge, there is no head-to-head
study comparing all modalities just for LV mass measure-
ment. Nevertheless, CCT seems to be a reasonable
method to evaluate LV function in well agreement with
CMR and because of superiority over echocardiography,
CV, and SPECT [39,40]. Despite good correlation with
respect to LV mass, 64-slice CCT was preferable to CMR
owing to better sensitivity and specificity for akinetic seg-
ments in patients with acute coronary syndrome. In con-
trast, 16-slice CCT was unable to repeat this result [41].
Although CCT entails many benefits, some limitations
are not negligible. Primary disadvantage is the inevitable
radiation exposure called as stochastic effect. In general,
radiation exposure is estimated to be between 7 and 21
mSv depending on the generation of the CCT and the use
of radiation-reducing algorithms [42]. This raised the
concerns about lung cancer and breast cancer risk for
repetitive use in daily practice, particularly in younger
people or women of childbearing age [43]. Unfortunately,
technical factors that enhance image quality result in a
higher radiation dose. Efforts to reduce the radiation dose
in CCT, which are not our present issue in this review,
has been discussed in depth [32,39,44]. Moreover, a sci-
ence advisory has been published regarding with ionizing
radiation in cardiac imaging and diligently conveys new-
est recommendations for cardiologists [45].
Contrast medium induced nephropathy is a caveat for
CCT in clinical practice. Calculating a simple risk score
for patient selection and new preventive pharmacological
measures are comprehensively discussed in a recent
report [46]. Another caveat for contrast agent is allergic
reactions, including severe anaphylaxis. Recommenda-
tions for handling these problems are debated previously
[47]. Thus, the need for iodinated contrast makes CCT
relatively contraindicated in patients at risk for contrast-
induced nephropathy or those with a history of allergy to
contrast media. Of interest, successful efforts concerning
LV mass detection with noncontrast CT as well as CMR
should also be realized to solve this problem [48].
High heart rate renders scan incompletely interpretable
with poor image quality because of motion artifacts.
Beta-blockers are usually administered prior to CT for
heart rate control and reducing motion artifacts, thus
improving image quality. Directions for patient prepara-
tion and beta-blocker administration are previously dis-
cussed in depth previously [47]. There was concern that
beta-blockers would have some impact on left ventricular
functional parameters. Nevertheless, administration of
beta-blockers is found to not affect LV mass assessment
[49]. Despite well tolerance to beta-blockers, this may
cause cautious observation and a prolonged stay of the
patient, which is unwelcomed. Instead, a segmental
reconstruction algorithm with CCT was alternatively
documented to be accurate and correlated well with CMR
over a broad range of heart rates without using beta-
blockers [39].
Cardiac rhythm is another determinant for better
image quality. Since MDCT angiography requires elec-
trocardiogram-gated acquisition and reconstruction
from several cardiac cycles, it is presently limited to
patients with stable, regular heart rates. Irregular cardiac
rhythm makes images suboptimal and even non-diagnos-
tic.
Obesity represents another challenge for CCT imaging.
Image resolution may be deteriorated in morbidly obese
patients because of x-ray attenuation. It is not yet clear
how CT should be integrated in the clinical practice for
patients with higher body mass index, who unfortunately
represent an increasingly prevalent segment today.
Given the predominant disadvantages of contrast
media application and radiation exposure, performing
CCT only for analysis of LV mass seems not reasonable.
Moreover, new generation CT such as 64-slice CT and
dual source-CT seems to enhance the clinical utilization
because of increased temporal resolution and reduced
acquisition time. Spatial resolution by contemporary CT
machines already outperforms the spatial resolution by
magnetic resonance (MR) imaging. This fortunately
comes at no additional cost of radiation dose or contrastCelebi et al. Cardiovascular Ultrasound 2010, 8:19
http://www.cardiovascularultrasound.com/content/8/1/19
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media delivery, as LV mass data is already delivered from
acquired data of CT coronary angiography.
Cardiovascular Magnetic Resonance
MR imaging is one of the newest and most exciting imag-
ing techniques in the cardiovascular armamentarium.
Official name is accepted as "cardiovascular magnetic
resonance" by the Society for Cardiovascular Magnetic
Resonance and declared in a statement when it is applied
to heart alone or heart and peripheral vascular structures
[32]. CMR has recently moved from a diagnostic tool
mainly used for congenital heart disease, large vessels,
pericardium, and tumors to a clinically proven, safe, and
comprehensive imaging modality with a broad range of
indications including LV mass quantification. Its appro-
priateness has been approved in order to assess LV mass
[50].
LV is not subject to any geometric assumption by CMR.
Major advantage of CMR is accuracy and reproducibility
by using 3D approach. Therefore, CMR is considered the
reference standard for both baseline and serial LV mass
measurements [11,13,51,52]. Furthermore, this technique
enables a reduction in sample size in clinical trials [51,52].
LV mass measurement by MR has eventually been in
excellent agreement with autopsy [53].
Its versatility is unmatched by any other individual
imaging modality. In addition to allowing for accurate
anatomic information, it also provides functional infor-
mation assisting in identifying patients at risk. Three-
dimensional left ventricular geometric analysis using
CMR yielded more accurate information about left ven-
tricular geometry compared to conventional echocardio-
graphic methods with higher reproducibility and lower
variability [54,55]. CMR is also able to detect LVH in
patients with seemingly normal echocardiographic
results [56]. This greater sensitivity is explained by geo-
metric assumption-free quantification of LV mass by
CMR.
L V mass measurement by CMR is very well suited to
clinical examinations: it is noninvasive, does not expose
the patient to ionizing radiation, and provides images of
high temporal resolution and excellent soft tissue con-
trast without the need for contrast medium injection.
Some other advantages are superior quality of images
mostly not limited by poor acoustic windows or operator
inexperience compared to echocardiography. Although
3DE removes the limitation of geometric assumption, it
disappointingly falls short of the limitation of poor acous-
tic window. When echocardiography is impractical in
patients with poor acoustic windows, CMR permits car-
diac structures to be imaged.
One of the end organ damages resulting from long-
standing hypertension (HT) is LVH. Detecting LVH is
strongly recommended in HT guidelines, as well [57].
Another objective is to detect remediable causes of HT in
guidelines. CMR is capable of demonstrating secondary
causes owing to availability of tissue characterization and
angiography along with LV mass assessment [58]. Hence,
CMR may be beneficial as a further comprehensive inves-
tigation modality when there is a suspect of secondary
HT, especially for aortic coarctation, renal artery stenosis
and surrenal gland related pathologies.
CCT suffers the burden of ionizing radiation and con-
trast medium that makes it less than ideal. Unlike CCT,
CMR is free of ionizing radiation or injection of poten-
tially nephrotoxic contrast medium. CMR can therefore
be repeated as often as necessary for follow-up and an eli-
gible alternative method to CCT (28). Despite previously
mentioned superiority of CCT about differentiation of
heart failure etiology, CMR may be an alternative and
guide therapy as long as CCT is contraindicated or
avoided [59].
In addition to presence and magnitude of LVH, its dis-
tribution can be determined by 2DE. Notwithstanding
this positive effect, CMR has been competitive with 2DE
respecting this issue. CMR is known to be highly more
effective in describing the degree, diversity, and extension
of LVH [60]. Apical views may also be exclusively subop-
timal in quality by 2DE. CMR is reported to demonstrate
apical region precisely and to be more accurate in the
diagnosis of apical hypertrophy than 2DE [61].
Myocardial fibrosis (MF) has reasonably known to be
associated with an increased risk of ventricular arrhyth-
mias [62]. Unique to CMR over other imaging modalities
is the characterization of tissue in high spatial resolution;
thereby detection of MF has become available by CMR.
This is an additional prognostic marker in addition to LV
mass in risk stratification. Thus, it makes CMR one-step
forward compared to other modalities.
Despite these promising results, several important limi-
tations of CMR should be kept in mind. It continues to
have problems of cost, limited availability, and lack of
portability. These limitations avert to use CMR routinely.
Contraindications for CMR traditionally exist with fer-
romagnetic metal devices such as a pacemaker or cardiac
defibrillator [52]. There are some justified reasons for
that; 1) There is potential risk of arrhythmias due to
induced lead currents, 2) The tips of the leads can get
extremely hot causing tissue damage, which can poten-
tially cause lead dysfunction, 3) It is also noticed that fer-
romagnetic metallic implants are liable to mechanical
pull and rotation of the device, 4) Image artifacts from
metallic implants may also preclude quantitative analysis.
In addition to these, concerns about implantable devices
have centered on the potential of CMR to inhibit the
function of the device and change programming. The
American Heart Association and the European Society of
Cardiology justifiably have issued statements on thisCelebi et al. Cardiovascular Ultrasound 2010, 8:19
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topic before [63,64]. According to these statements, CMR
m a y  b e  c o n s i d e r e d  a f t e r  c a r e f u l  e v a l u a t i o n  i n  s e l e c t e d
patients, only done when clinically indicated in the
absence of an alternative imaging modality, and the diag-
nostic benefit from MR must outweigh the presumed
risks. In addition to these measures, new MR compatible
pacing systems are designed to confirm the safety and
efficacy in the MR environment and to probably remove
these challenges. The interim results of a recent study of
these devices are fortunately encouraging [65].
Claustrophobia becomes a remarkable problem in
some patients. Mild sedation may handle the limitation of
claustrophobia [51]. Open magnets also appear to elimi-
nate this limitation in the near future.
Another criticism for CMR has been duration of analy-
sis to obtain LV mass data. Now, faster semiautomatic
border definition procedures seem to make time problem
unlikely as for CT and 3DE [51]. This procedure provides
accurate and quick assessment of LV mass. Recent break-
throughs in CMR technique can supersede repeated
breath holding for analysis and help shorten acquisition
time [66,67].
One potential drawback of CMR may be the increased
risk of nephrogenic systemic fibrosis (NSF) by virtue of
gadolinium in acute and chronic renal failure [68]. In
these cases, gadolinium-based contrast agents should be
avoided unless it is essential and other imaging modalities
should be preferred. FDA has requested that the manu-
facturers include a new Boxed Warning and new warn-
ings section in the labels that describe the risks of
developing NSF.
CMR provides a noninvasive, accurate, and reproduc-
ible LV mass assessment without radiation, contrast
agent, and geometric assumption. The clinical role of
magnetic resonance in diseases of the heart and great
vessels is rapidly evolving. Besides, some applications of
MR to the cardiovascular system are now established
components of a cardiac workup. Despite these benefits,
CMR has yet to fill this role because of cost, availability,
and more minor issues regarding device incompatibilities
and patient tolerance for routine clinical use. Further-
more, most studies have used 1.5 T magnets. Clinical 3-T
MR systems are becoming widespread and their role
awaits further investigation.
Single Photon Emission Computed Tomography
SPECT is another imaging modality for LV mass assess-
ment. SPECT, using a variety of protocols and with either
thallium-201 or technetium-99 m tracers can be used for
gated perfusion purposes. Thus, SPECT should particu-
la r ly  be  fa vou r ed in pa t ie n ts wit h s us pect ed or  kno wn
coronary artery disease.
Several limitations of SPECT merit attention. Firstly,
this technique is rather expensive and becomes impracti-
cal when serial evaluation is essential. Secondly, it inher-
ently involves radiation and 85% of the radiation of
nuclear medicine studies arises from cardiac imaging
modalities [51,69]. Radiation exposure is estimated to be
approximately 9 mSv for 99 mTc stress/rest and 41 mSv for
201Tl stress/rest [42]. As discused before, recommen-
dations for the safe use of cardiac imaging with radia-
tion exposure are discussed in depth [45]. Cumulative
radiation dose from SPCET for multiple follow up pose
a problem for long-term follow up. Therefore, echocar-
diography or CMR, which can be performed repeatedly,
may be a rational option in this setting. Thirdly, partial
volume effect and limited image resolution may lead to
inaccurate measurement in the event of small heart [51].
Fourth limitation is the presence of large perfusion
defects disabling calculation of LV mass. Finally, it is sub-
ject to low spatial and temporal resolution [51].
SPECT permits perfusion assessment of myocardium
and LV function encompassing LV mass within a single
study. However, SPECT, with taking into account its infe-
riority to other imaging modalities for LV mass assess-
ment, should not be standard.
Contrast Ventriculography
CV allows estimation of LV mass along with coronary
anatomy. Although CV was introduced to clinical prac-
tice before above-mentioned methods, it was left under
used and neglected in due course. This forgotten method
was once called as the reference method for LV mass
evaluation [70]. Calculation of LV mass using CV was in
accordance with actual weights in postmortem human
hearts [71]. This method may decrease downstream test-
ing costs, such as echocardiography, CCT, and CMR.
Therefore, CV may possibly confer the most cost-effec-
tive modality for LV mass assessment in patients under-
going left heart catheterization [72].
This method is subject to some limitations. Pericardial
diseases such as effusion or thickening may invalidate this
method. RV hypertrophy may also lead to erroneous
measurement of LV mass. Pulmonary lesions that
obscure left heart border additionally may preclude
assessment of LV mass with this method. Suboptimal
opacification will make accurate LV mass measurement
unlikely. If lateral wall does not appear to be representa-
tive of whole LV (aneurysm, asymmetric LVH), this
method may give unreliable measurement. Its invasive-
ness, radiation exposure, and contrast media are finally
other points of concern disabling it in clinical practice.
Conclusion
Conventional echocardiography currently continues to
be the imaging modality of choice for the assessment of
LV mass in routine clinical practice. Unfortunately, con-
ventional echocardiography has been marred by manyCelebi et al. Cardiovascular Ultrasound 2010, 8:19
http://www.cardiovascularultrasound.com/content/8/1/19
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limitations in spite of advancements in hardware and
software technology. Evaluation of LV mass is now feasi-
ble by various diagnostic imaging modalities other than
conventional echocardiography. CMR evenly offers opti-
mal and reference standard for LV mass assesment. CCT
and 3DE are comparatively still experimental, whereas
SPECT and CV seem to fall in oblivion. However, before
extensive use, these methods need to be thoroughly
Table 1: Comparison between different techniques.
Technique Advantages Disadvantages
M-mod echocardiography -safe,
-rapid,
-cost-effective,
-available,
-portable,
-highly versatile,
-noninvasive
-limited in patients with poor acoustic image (obese and chronic 
obstructive pulmonary disease) and asymmetric LV
-operator dependent
2DE -safe,
-rapid,
-cost-effective,
-available,
-portable,
-highly versatile,
-noninvasive
-limited in patients with poor acoustic image (obese and chronic 
obstructive pulmonary disease) and asymmetric LV ,
-operator dependent
3DE -safe,
-rapid,
-cost-effective,
-available,
-portable,
-versatile
-highly versatile,
-noninvasive
-limited in patients with poor acoustic image (obese and chronic 
obstructive pulmonary disease)
CMR -safe
-highly versatile,
-noninvasive -reproducible
- Limited in claustrophobic patients, acute and chronic renal failure or 
those with metallic implants,
-long testing time,
-expensive,
-not portable,
-limited availability
CCT -medium versatile,
-noninvasive
- Limited in patients with arrhythmia or obesity,
-long testing time,
-radiation exposure,
-limited for serial studies,
-not portable,
-contrast agent exposure
SPECT -medium versatile,
-noninvasive
-long testing time,
-radiation exposure,
-limited for serial studies,
-not portable,
-expensive
CV -medium versatile, -invasive,
-radiation exposure,
-not portable,
-contrast agent exposure,
Limited in patients with pulmonary, and pericardial diseaseCelebi et al. Cardiovascular Ultrasound 2010, 8:19
http://www.cardiovascularultrasound.com/content/8/1/19
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tested in larger studies and validated in distinct patient
populations. Every patient should be considered in his or
her own condition due to lack of established guidelines in
terms of LV mass assessment. All modalities need to be
taken into account in the context of their specific advan-
tages and disadvantages (table 1). The near future holds
major developments that may eliminate some of the dis-
advantages. Good communication between cardiologist
and radiologist is becoming obviously crucial to track the
appropriate use of imaging tests in clinical practice.
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